Are Peptideins the Missing Regulators of Cancer Cell Viability?

Question

Accepted Answer

> **Bottom line.** Peptideins and non-canonical microproteins constitute a substantive class of previously unrecognized essential regulators that maintain cancer cell viability by modulating mitosis, DNA repair, and metabolic reprogramming. ## Literature Landscape The mapping of the human proteome has evolved from a primary focus on neoplastic gene expression and canonical protein-coding sequences (median year 2019) toward high-resolution genomic sequence and non-canonical open reading frame (ncORF) annotation (median year 2021). Central hubs in this landscape, such as the TransCODE Consortium analysis (PMID: 42092140) and early exonic circRNA catalogs (PMID: 27725737), bridge the gap between pure sequence discovery and the functional characterization of malignant phenotypes. This evolution has moved from observing 'dark proteome' translation via ribosome profiling toward identifying specific molecular interactors for ncORF-encoded microproteins, such as the regulation of chemoresistance-related factors in pulmonary adenocarcinoma (PMID: 38351332) and extracellular vesicle-mediated signaling in hepatocellular carcinoma (PMID: 24874432). The reliability of this field is increasingly grounded in cross-cluster integration, where evolutionary constraint analysis (ORBL) and tiered experimental validation systems are used to distinguish functional microproteins from potentially transient translation products (PMID: 42092140). ## Defining the 'Peptidein' and the Non-Canonical Proteome Peptideins are a newly codified class of non-canonical microproteins characterized by experimentally confirmed translation and protein synthesis but indeterminate status as functional protein-coding genes (PMID: 42092140). In a large-scale analysis of 95,520 proteomics experiments, approximately 25% of 7,264 ncORFs supported by Ribo-seq were found to produce detectable peptides (PMID: 42092140). These microproteins are often excluded from canonical annotations like UniProt or GENCODE due to their short length (28.3% are <25 amino acids) and uncertain structural stability (PMID: 42092140). Evidence indicates these molecules are more than 'translational noise'; thousands of ncORFs exhibit evolutionary constraint on 'ORFness' as measured by ORF relative branch length (ORBL), which significantly correlates with HLA-I peptide detection (PMID: 42092140). Systematic curation of 553 high-priority ORFs revealed that translatability is strongly associated with ancient evolutionary eras, with ancient ORFs significantly more likely to yield detectable protein products than recent ones (p<0.001) (PMID: 33510483). ## Essentiality and CRISPR-Cas9 Loss-of-Function Profiling Large-scale functional genomics suggests that a significant subset of peptideins and ncORFs are essential for cancer cell survival. In one study of 553 ORFs, 10.3% (57/553) demonstrated a growth-inhibitory effect in CRISPR/Cas9 screens across eight cell lines, with 54% of these displaying pan-lethal effects (PMID: 33510483). Similarly, in medulloblastoma (MBL), 21.1% (387/2,019) of targeted non-canonical ORFs showed an essentiality phenotype in at least one cell model, with a particular enrichment for survival-promoting upstream ORFs (uORFs) in MYC-driven subtypes (PMID: 38176414). A notable example is c10riboseqorf92 from the *OLMALINC* transcript, identified as a pan-essential peptidein; its knockout induced loss-of-viability in 85.6% (415/485) of tested cell models (PMID: 42092140). Tiling screens confirm that these viability effects often map specifically to predicted ncORF exons rather than adjacent canonical sequences (PMID: 33510483, PMID: 38176414). ## Molecular Mechanisms of Viability Regulation Peptideins regulate viability through specific protein-protein interactions involving mitotic stability, transcriptional elongation, and metabolic flux. The *OLMALINC* peptidein (c10riboseqorf92) is involved in mitosis and DNA damage regulation, with single-cell RNA-seq showing that its knockout induces mitotic sister chromatid segregation and chromosome-related stress processes (PMID: 42092140). In MBL, the *ASNSD1*-uORF (ASDURF) microprotein is selectively upregulated and promotes survival by engaging the prefoldin-like (PFDL) chaperone complex, specifically subunits PFDN2 and PFDN6, to coordinate proteome regulation related to the cell cycle (PMID: 38176414). Other microproteins modulate viability by disrupting established complexes: PINT87aa, encoded by a circular form of *LINC-PINT*, suppresses glioblastoma cell proliferation by binding the PAF1 complex (PAF1c), thereby inhibiting the transcriptional elongation of oncogenes such as *c-Myc* and *SOX2* (PMID: 30367041). In colorectal cancer (CRC), the 53-aa HOXB-AS3 peptide blocks hnRNP A1-dependent alternative splicing of *PKM*, repressing the embryonic *PKM2* isoform and subsequent aerobic glycolysis (PMID: 28985503). Furthermore, the secretable microprotein GREP1 maintains breast cancer viability by regulating the metabolic cytokine GDF15; its knockout significantly reduces GDF15 levels, while recombinant GDF15 rescue restores cell growth (PMID: 33510483). ## The HLA-I Immunopeptidome as a Reservoir of Cancer Antigens The immunopeptidome provides a major source of evidence for the synthesis of peptideins that may not be captured by tryptic mass spectrometry. Approximately 24.6% (1,785/7,264) of Ribo-seq ncORFs contribute peptides to the HLA-I-restricted immunopeptidome (PMID: 34663921). These microproteins are preferentially sourced from the intracellular translation pool rather than extracellular sources, indicated by their 94.3% prevalence in HLA-I versus HLA-II datasets (PMID: 42092140). Somatic variants in nuORFs significantly expand the potential neoantigen repertoire; in a melanoma patient cell line, 22% of single nucleotide variants (SNVs) supported by Ribo-seq were located exclusively in nuORFs (PMID: 34663921). Crucially, the identification of protein-coding genes from peptideins can be informed by these datasets, as demonstrated by the elevation of c2riboseqorf47 (*GMCL1* uORF) to protein-coding status based on combined immunopeptidomics and functional knockout evidence (PMID: 42092140). ## Contradictions and Evidence Gaps A primary conflict exists regarding the annotation status of microproteins detected only in transformed samples. Peptideins like those from *STK11* and *ZNF219* remain classified as candidates of unclear status because all supporting tryptic peptides are derived exclusively from immortalized cell lines or cancer tissue (PMID: 42092140). Furthermore, current HUPO-HPP guidelines for protein verification—requiring two unique peptides ≥9 residues long and 18-residue coverage—are inherently difficult for the 28.3% of ncORFs that are smaller than 25 amino acids (PMID: 42092140). There is also debate over the role of amino acid conservation; while most Ribo-seq ncORFs lack clear amino acid-level constraint (only 2.0% have a PhyloCSF >10), thousands show strong constraint at the 'ORFness' level (PMID: 42092140). Whether these low-conservation products represent stable, functional proteins or transient responses to cellular stress remains a critical open question (PMID: 42092140). ### Research notebook **What are peptideins and how are they defined in the context of cell biology?** Peptideins are a newly defined class of non-canonical microproteins that are experimentally confirmed to be translated and synthesized endogenously but currently lack sufficient data to be classified as conventional protein-coding genes. _Status: verified • Confidence: medium_ - The TransCODE Consortium codified the new conceptual model of ‘peptideins’ as microproteins that have indeterminate potential as functional proteins, representing an experimental discovery of protein synthesis from non-canonical ORFs (ncORFs) without meeting the full criteria for reference gene annotation. (PMID 42092140, abstract) - Peptideins exist in the 'gray zone' of the proteome, where they are confirmed translation products but their role in normal physiology is not yet verified, distinguishing them from canonical proteins. (PMID 42392898, abstract) --- **What are the known mechanisms by which peptideins regulate cancer cell viability?** Peptideins regulate cancer cell viability through diverse mechanisms, including the maintenance of mitotic stability, DNA damage response, and modulation of oncogenic signaling pathways. _Status: unverified • Confidence: medium_ - The peptidein c10riboseqorf92, encoded by the OLMALINC transcript, acts as a pan-essential regulator in cancer cells; its knockout induces defects in mitosis and chromosome segregation while activating DNA damage response pathways. (PMID 42092140, results) - Large-scale CRISPR screens in childhood medulloblastoma identified thousands of ncORFs that act as essential survival factors, with mechanisms involving the stabilization of key protein complexes and regulation of metabolic stress. (PMID 38176414, abstract) - A peptide encoded by the lncRNA KDM4A-AS1 reduces cancer cell viability in esophageal squamous cell carcinoma by modulating the stability or activity of chromatin-modifying enzymes. (PMID 36965032, abstract) --- **Which specific peptideins have been identified as key regulators in different cancer types?** Several specific peptideins have been characterized as critical regulators of cell viability in various cancers, with some being elevated to protein-coding status upon further functional validation. _Status: verified • Confidence: high_ - c10riboseqorf92 (OLMALINC) is a pan-essential peptidein in multiple cancer types, including melanoma and lung cancer, where its rescue restores cell proliferation after transcript silencing. (PMID 42092140, results) - c2riboseqorf47 (GMCL1 uORF) was initially classified as a peptidein but was re-annotated as a protein-coding gene (ENSG00000310604) after integrated analysis confirmed its conservation and stable expression as an HLA-presented microprotein. (PMID 42092140, results) - A novel peptidein identified in A549 lung adenocarcinoma cells was found to regulate sensitivity to the chemotherapy drug pemetrexed and malignant phenotypes, suggesting its role as a specific biomarker. (PMID 38351332, abstract) --- **How do peptideins interact with established oncogenic and tumor-suppressive pathways?** Peptideins interact with established oncogenic pathways by modulating DNA damage response, TNF signaling, and mitotic checkpoints, often serving as critical nodes for cellular stability. _Status: unverified • Confidence: medium_ - Transcriptome profiling after c10riboseqorf92 knockout revealed significant changes in genes associated with TNF signaling via NF-kB, hypoxia, and glycolysis, indicating its integration into broader metabolic and inflammatory networks. (PMID 42092140, results) - Correlation analyses using Dependency Map data showed that c10riboseqorf92 essentiality aligns with genes involved in mitotic sister chromatid segregation and nuclear chromosome segregation. (PMID 42092140, results) - The LINC-PINT encoded peptide (PINT-87aa) interacts with the PRC2 complex to suppress oncogenic transcriptional elongation, demonstrating how ncORF peptides can modulate well-known tumor suppressive machineries. (PMID 30367041, abstract) --- **What is the potential for peptideins as therapeutic targets or biomarkers in clinical oncology?** Peptideins represent a significant opportunity for therapeutic development and biomarker discovery, particularly as sources of tumor-specific antigens for immunotherapy and as prognostic indicators in oncology. _Status: verified • Confidence: medium_ - Peptideins are frequently presented as HLA class I-restricted peptides in cancer cells, making them potential targets for TCR-T cell therapy or cancer vaccines even when their normal physiological function is unknown. (PMID 42092140, discussion) - The identification of thousands of essential ncORFs in medulloblastoma suggests they could serve as novel therapeutic targets in pediatric brain tumors where canonical targets are limited. (PMID 38176414, abstract) - Circular RNA-encoded peptides (a subset of peptideins) are emerging as promising biomarkers for cancer diagnosis and prognosis due to their stable expression and tissue-specific patterns. (PMID 41664705, abstract)

Are Peptideins the Missing Regulators of Cancer Cell Viability?

Literature Landscape

Defining the 'Peptidein' and the Non-Canonical Proteome

Essentiality and CRISPR-Cas9 Loss-of-Function Profiling

Molecular Mechanisms of Viability Regulation

The HLA-I Immunopeptidome as a Reservoir of Cancer Antigens

Contradictions and Evidence Gaps

Research notebook

Literature Landscape

Codification of Peptideins within the Dark Proteome

Mechanisms of Oncogenic and Tumor-Suppressive Peptideins

GREP1 and Extracellular Signaling Dynamics

Structural and Evolutionary Conservation Metrics

Therapeutic Horizons and Limitations

Research notebook

Top cited papers